NVIDIA Locks Lilly and Thermo Fisher Into BioNeMo as Global Drug Discovery Platform Race Intensifies
NVIDIA's BioNeMo has secured partnerships with Eli Lilly and Thermo Fisher, making GPU-backed protein modeling the shared infrastructure layer for commercial drug discovery. Five global competitors — including France's Owkin and UK-rooted Basecamp Research — are targeting the same stack. Platform decisions made in 2026 will determine which pipelines reach clinical trials by 2028.
Salvado•